Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of EDAP TMS SA

NEW YORK, Aug. 1, 2014

The investigation focuses on whether the Company and certain of its executives violated federal securities laws.

On July 28, 2014, EDAP announced that Food and Drug Administration ("FDA") staff questioned the Company's safety and effectiveness data because the Company compared patients in two different studies to gather evidence, rather than a head-to-head trial. The investigation also relates to the FDA's July 30, 2014, announcement that the panel convened to review EDAP's submission unanimously found that EDAP had failed to demonstrate the efficacy of its product or that it had demonstrated that the benefits of the device outweighed its risk. 

On this news, shares of EDAP fell $1.48 or 43.27% during intraday trading to trade at $1.94 on July 31, 2014.

If you are aware of any facts relating to this investigation, or purchased shares of EDAP TMS SA, you can assist this investigation by contacting Edward N. Gewirtz or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com.  Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Edward N. Gewirtz or Eitan Kimelman 212-697-6484
info@bgandg.com